Table of Contents

Table of Contents

Featured Article

Understanding the Impact of COVID-19 on Corneal Transplant Need and Demand through the Example of Australia

Letter from Editor

Letter from the Editor

Research / Proceedings

Autopsy Final Report Findings and Corneal Transplantation: A Retrospective Review

Corneal Transplantation from Donors Serologically Positive for Trypanosoma cruzi

Alterations In the Measured Intraocular Pressure Following Corneal Collagen Cross Linking

Abstracts from 2020 Eye Bank Association of America Scientific Symposium

Autopsy Final Report Findings and Corneal Transplantation: A Retrospective Review


Ellen L. Heck, MT (ASCP) MA, Valerie Corder BSRN, Richard Jordan, BA, CEBT, Jill Urban M.D., Dwight Cavanagh M.D. PhD


Donor screening for the possible introduction of a transmissible disease is a paramount concern for eye bankers, the Food and Drug Administration, (FDA), and the Eye Bank Association of America, (EBAA). The combination of the donor risk assessment interview or (DRAI) and the mandated serologic testing for infectious viral disease markers has been highly successful in assuring the safety of allograft tissues for transplantation. However, especially for cornea transplantation due to the time limits for maximum viability of the endothelial cells needed to restore vision, information that might have adversely affected the determination of donor eligibility does not become available until after the tissue has been transplanted. This retrospective study reviews histology findings and autopsies where myocarditis, or other potential contraindication was not reported until days or weeks after the corneal transplantation had occurred.

Article PDF

Fullscreen Mode